Showing results (11-20 of 67) with videos related to
Sort By:
Pageof 7
Plos One|May 9, 2012
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary taleSheila Harris, Madeleine Craze, Jillian Newton, et al.Chemmedchem|October 4, 2018
Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer TherapyAndrew W Brown, Toby Holmes, Matthew Fisher, et al.The British Journal of Radiology|August 31, 2018
Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapyChryso Kanthou, Gillian TozerScientific Reports|June 20, 2020
The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphateToby Holmes, Andrew W Brown, Marie Suggitt, et al.International Journal of Cancer|December 15, 2010
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphateSarah Jane Lunt, Simon Akerman, Sally A Hill, et al.Anticancer Research|August 21, 2003
The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitroAndrew C Brooks, Chryso Kanthou, Ian H Cook, et al.Biosensors|July 28, 2023
Wearable Insulin Biosensors for Diabetes Management: Advances and ChallengesSotiria D Psoma, Chryso KanthouBMC Cancer|December 13, 2006
Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expressionGabi U Dachs, Andrew J Steele, Claudia Coralli, et al.Cancer Research|April 6, 2017
Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in SarcomaWilliam R English, Sarah Jane Lunt, Matthew Fisher, et al.Plos One|August 15, 2014
Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristicsChryso Kanthou, Gabi U Dachs, Diane V Lefley, et al.Pageof 7